newsfilter
← Latest News
GlobeNewswire·

Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ:PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment an